Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Exelixis, Inc. and Prometheus Laboratories Inc.
An Ancillary Satellite Symposium Held Adjunct to The Oncology Nursing Society Annual Meeting
Hyatt Regency Denver – Capitol 1-3
650 15th Street
Denver, CO 80202
Renal cell carcinoma (RCC) remains one of most challenging solid tumors to treat. However, RCC therapy is also one of the most rapidly evolving fields in oncology. Since the mid-2000s, the emergence of anti-angiogenic compounds and mTOR inhibitors has changed the therapeutic landscape, where current frontline approaches involve the use of a VEGFR inhibitor, followed at disease progression by a number of potential targeted and immunotherapeutic approaches.
There have been several recent drug approvals, and promising novel mechanistic and combination approaches are currently being evaluated as treatment for patients with these tumors. As a key member of the RCC treatment team, the oncology nurse has a pivotal role in the implementation of best practices to appropriately use and sequence therapies and to mitigate and manage treatment-related adverse events. This can be particularly challenging for healthcare providers who manage RCC, given how quickly this field has progressed recently and continues to evolve.
This activity will bring together renowned experts in RCC treatment and care for an in-depth discussion on the clinical impact of recent and emerging trial data in RCC. Presentations will be designed to illuminate the nurse’s role in RCC patient management decisions related to sequencing and switching based on patient and disease characteristics, adverse event management, and communication with patients. Future directions in the field will also be addressed and considered in regard to how recent developments and highly anticipated trials may shape care in the near future. Faculty will be present onstage throughout the program for structured discussions, and the program will conclude with an expert panel that will illustrate nursing best practices through case-based discussion. Audience participation will be integrated throughout to encourage interaction with faculty and engagement with the content.
This educational activity is directed toward all attendees of the 42nd ONS Annual Congress, including nurses and other healthcare professionals in the oncology space./p<>
Upon completion of this activity, participants will be better prepared to:
- Explain the mechanistic rationale that underlies targeted drug development for the treatment of renal cell carcinoma (RCC).
- Report major findings from landmark clinical trials in advanced RCC and how evidence informs sequencing and switching among different treatment strategies
- Apply best nursing practices to proactively manage treatment-related toxicities in patients with RCC
- Evaluate case-based clinical scenarios to determine optimal treatment strategies and methods to mitigate treatment-related toxicities when managing advanced RCC in multiple lines of care
- Summarize the next steps in RCC research and ongoing clinical trials whose results are highly anticipated in the field
Laura S. Wood, RN, MSN, OCN
Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Institute
April 29, 2017
New York, NY
Cancer Summaries and Commentaries™: 2016 Conference Coverage: Advances in the Treatment of Genitourinary Cancers
Apr 29, 2017